Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin + Oral Irinotecan in AYA Solid Tumors
NCT02596503Phase 1Completed
- Sponsor
- University of Colorado Denver
- Start
- Oct 2015
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eribulin in solid tumor, sponsored by University of Colorado Denver. Primary endpoint: Recommended Phase II Dose at 2 years. Started Oct 2015; status: completed.
02
Drugs
eribulin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02596503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02596503.